New hope for Tough-to-Treat breast cancer? scientists test Triple-Threat drug combo

NCT ID NCT03939897

Summary

This study is testing if adding a new drug called copanlisib to the standard two-drug treatment (fulvestrant and abemaciclib) is more effective for advanced breast cancer that has stopped responding to hormone therapy. It will involve about 24 patients with hormone-positive, HER2-negative breast cancer that has spread. The main goal is to find the safest dose of the three-drug combination and see if it works better to control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bellevue Hospital Center

    New York, New York, 10016, United States

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York, 10016, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri, 63136, United States

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri, 63376, United States

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri, 63141, United States

  • Siteman Cancer Center-South County

    St Louis, Missouri, 63129, United States

  • UC Irvine Health Cancer Center-Newport

    Costa Mesa, California, 92627, United States

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California, 92868, United States

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, 35233, United States

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky, 40536, United States

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157, United States

  • Wake Forest University at Clemmons

    Clemmons, North Carolina, 27012, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.